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access article under the CC BY-NC-NDSummary Background/objective: When researchers or developers wish to apply their find-
ings to clinical usages, it must be approved by public authorities such as the US Food and Drug
Administration (FDA). In addition to the development records and risk control documents, all
of the materials and testing must be completed by laboratories or manufacturers with good
quality controls in accordance with related regulations or standards. The Orthopaedic Device
Research Center dynamic hip screw system (ODRC-DHS system), which was developed by the
ODRC, National Yang-Ming University, Taipei, Taiwan, obtained FDA 510(k) clearance in 2011.
Methods: The application process was divided into five steps: (1) make sure that the product is
a medical device and classify it; (2) find the predicate devices cleared by the FDA; (3) research
any standards and/or guidance documents; (4) prepare the appropriate information for
premarket submission to the FDA; and (5) send premarket submission to the FDA and interact
with the FDA staff.
Results and Conclusion: The relevant regulations, guidelines, and strategies were detailed by
step-by-step demonstration so that readers can quickly understand the requirements and
know-how of a translational research.
ª 2016 The Authors. Published by Elsevier (Singapore) Pte Ltd on behalf of Chinese Speaking
Orthopaedic Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Many organizations use Science Citation Index (SCI) papers
to assess the performance of researchers. However,ing, 2F, Number 155, Section 2,
il.com (C.-K. Cheng).
.06.027
hed by Elsevier (Singapore) Pte Lt
license (http://creativecommonengineers in undeveloped or developing countries could
seldom read SCI papers due to language barriers or reading
habits. This phenomenon means that the research results of
these countries are unable to provide any substantialLi-Nung Street, Beitou District, Taipei, Taiwan.
d on behalf of Chinese Speaking Orthopaedic Society. This is an open
s.org/licenses/by-nc-nd/4.0/).
From SCI to FDA 31benefit to citizens. Therefore, translational research which
not only profits the research team but also benefits the
people has become very important.
To translate a research result into a legal medical de-
vice, additional evidence or documents are needed to
ensure the quality and consistency of a product, such as the
demonstration of contraindications, the approaches in
reducing the risk, and the controls of production processes
including manufacturing, cleaning, and sterilization. The
requirements for a SCI paper and a medical device are
summarized in Table 1.
A medical device is intended for use in saving or pro-
tecting the health of individuals, therefore it should not be
used if the foreseeable risks clearly outweigh the benefits
of use. For this reason, public authorities pay more atten-
tion to the risks and quality control of medical devices.
They have set documents of regulations and/or guidance
for medical devices, which must be fully complied with, to
ensure the safety and effectiveness of devices [1e5]. The
best strategy for preparing the submission of a medical
device is to follow the available methods and the interna-
tional standards and guidance documents. If existing reg-
ulations, standards or guidances cannot be found, it is
possible that it is a new device and classed as Class III.
Therefore, it may need to follow the premarket approval
(PMA) submission process.
In different countries, the medical device classification
and the required documents for license can be quite varied.
The following introduction focused on the United States
Food and Drug Administration (US FDA) criteria. Applicants
can adopt the following steps prior to marketing a medical
device in the US:
Step 1: Make sure that the product is a medical device
and classify it.
Medical devices marketed in the US are subject to the
regulatory controls in the Federal Food, Drug and Cosmetic
Act (FD&C Act) [1] and the regulations in the Title 21- Code
of Federal Regulations (21 CFR) Parts 1e58, 800e1299.
According to the definition in Section 201(h) of the FD&C
Act, a medical device is:
“an instrument, apparatus, implement, machine,
contrivance, implant, in vitro reagent, or other similar orTable 1 General Requirements for SCI papers and medical
devices.
SCI paper Medical device
Indicationsa Yes Yes
Contraindicationsb No Yes
Effectiveness Yes Yes
Safety No Yes
Quality system No Yes
SCIZ Science Citation Index.
a Indications denote the disease or condition the device will
diagnose, treat, prevent, cure, or mitigate, including a
description of the target patient population.
b Contraindications denote when the device should not be
used.related article, including a component part, or accessory
which is:
 recognized in the official National Formulary, or the
United States Pharmacopoeia, or any supplement to
them,
 intended for use in the diagnosis of disease or other
conditions, or in the cure, mitigation, treatment, or
prevention of disease, in man or other animals, or
 intended to affect the structure or any function of the
body of man or other animals, and which does not
achieve its primary intended purposes through chemi-
cal action within or on the body of man or other animals
and which is not dependent upon being metabolized for
the achievement of any of its primary intended
purposes.”
Many researchers believe that their products are med-
ical devices, however, the products may not meet the
above definitions. This will lead to unsuccessful licensing
of the products. Medical devices are categorized into
three classifications according to the risks of the devices
by the US FDA as Class I, Class II and Class III (Table 2)
according to Section 360c(a) of the FD&C Act [1]. The risks
that a device poses to patients and the FDA regulatory
control vary with the classifications. Medical devices in
Class I typically possess simple designs and construction
that present minimal potential harm to users with a his-
tory of safe use, so they should only comply with general
controls. Medical devices in Class II are those whose suf-
ficient safety and effectiveness cannot be assured by
general controls, although the existing methods and the
international standards and guidance documents are
available to provide scientific evidences of safety and
effectiveness. As well as complying with general controls,
devices in this classification must conform to special
controls. Premarket notification, i.e., submission and the
FDA review of a 510(k) clearance, is required for the legal
marketing of some Class I devices, nearly all Class II de-
vices, and a very small number of Class III devices. Class III
devices are usually used for supporting or sustaining
human’s life, or preventing a potential unreasonable risk
of illness or injury in patients. The most stringent regu-
latory controls are set for Class III medical devices because
the information provided by general controls and special
controls is insufficient to assure safety and effectiveness.
Typically, a PMA submission to the FDA is required in order
to market a Class III medical device.Table 2 FDA medical device classifications.
Classifications a Risk Level of regulatory control
Class I Minimal General controls
Class II Medium General controls and
special controls (510k)
Class III High General controls and PMA
FDAZ Food and Drug Administration; PMAZ premarket
approval.
a The classifications are according to Section 360c(a) of the
FD&C Act [1].
32 H.-C. Kao et al.It is very difficult for applicants to classify the products.
Fortunately, the FDA has a classification database to help
people finish this step [6]. Applicants can use this database
by typing the name of a product with simple related terms
to make sure that the classification of the product matches
with the descriptions provided.
Step 2: Find the predicate devices cleared by the FDA.
The predicate devices mean the similar medical de-
vices that have already been cleared by the FDA. An FDA
510(k) submission is based on the comparisons of products
with the predicate devices. The FDA 510(k) database is
the best way to find the predicate devices [7].
Step 3: Research any standards and/or guidance
documents.
International Organization for Standardization (ISO)
14971 is one of the most useful standards [8]. It states:
“This International Standard specifies a process for a
manufacturer to identify the hazards associated with
medical devices, including in vitro diagnostic (IVD) medical
devices, to estimate and evaluate the associated risks, to
control these risks, and to monitor the effectiveness of the
controls.” It provides an overview of the risk management
process for medical devices and a series of questions that
can be used to identify the characteristics of medical de-
vices which could impact on safety. Following the process,
the risks of medical devices can be evaluated systemati-
cally. The most common risks of orthopaedic devices
include biocompatibility (e.g., toxicity of chemical con-
stituents) and mechanical energy hazards (e.g., torsion,
shear or tensile force). These risks must be reduced to an
acceptable level. The main factors which would cause the
above-mentioned risks are raw materials and the quality
control of a production process. Inappropriate raw mate-
rials may have a composition that has adverse effects on
human. The contamination, inadequate cleaning, or ster-
ilizing process during processing may increase biocompati-
bility concerns. Furthermore, undesirable mechanical
properties of use or poor processing quality could affect the
effectiveness of orthopaedic devices or even increase the
risk of failure.
When preparing the 510(k) documents for submission, it
is most important to provide sufficient evidence of
effectiveness and safety of the product. It is necessary to
prove that the product would not cause adverse reactions
in patients, i.e., the biocompatibility of the product. ISO
10993 is a part of the international harmonization of the
evaluation of safety of medical devices, which entails a
series of standards for evaluating the biocompatibility. ISO
10993-1:2009 [9] describes the general categorization of
devices based on the nature and duration of their contact
with body and suggests the necessity of biocompatibility
tests. It will take a lot of time and cost to complete those
tests.
In order to reduce potential biocompatibility risks, The
American Society for Testing and Materials (ASTM) and ISO
have established the standards for materials commonly
used for orthopaedic devices, such as metallurgical,ceramic and polymeric materials [10e12]. Both chemical
compositions and mechanical properties of materials for a
surgical implant are clearly defined in these standards.
Using certified medical grade materials to produce ortho-
paedic devices is the easiest way to meet the regulatory
requirements.
Additionally, it is necessary to strengthen the quality
control of manufacturing processes. ISO 13485 [13] is
an excellent reference standard which specifies not
only the control of the premarket product design, the
manufacturing process and the product quality, but also
the control of the postmarket surveillance. An ISO 13485
certificate represents that the production quality of the
manufacturer reaches a fairly high level. Unqualified
products or unstable quality between lots are unlikely to
happen. Therefore, the common risks of medical devices
can be reduced greatly by contracting out to a facility
which holds an ISO 13485 certificate.
Usually, the effectiveness and security of orthopaedic
devices are evaluated through mechanical tests. Unfortu-
nately, it is difficult to compare test results from different
laboratories due to the differences in testing equipment
and parameters. Therefore, the ASTM and ISO developed a
series of mechanical testing standards for orthopaedic de-
vices, for example, ASTM F382 [14] and ISO 9585 [15] are
the testing standards for bone plates, and ISO 7206-4 [16]
and ISO 7206-6 [17] are the testing standards for hip pros-
thesis at different parts. Based on the indications and
characteristics of orthopaedic devices, appropriate stan-
dards should be followed so that the credibility of the test
results will be increased and accepted easily by public
authorities.
Step 4: Prepare the appropriate information for
premarket submission to the FDA.
In order to confirm the effectiveness and safety of a
product, a lot of inevitable testing must be completed. But
how can the credibility of the test reports be confirmed?
ISO/International Electrotechnical Commission (IEC) 17025
[18] is the most important standard for calibration and
testing laboratories around the world. Laboratories that are
accredited to this international standard have demon-
strated that they are technically competent and able to
produce precise and accurate tests and/or calibration data.
The FDA does not enforce the qualifications of testing
laboratories. However, if a test report is completed by a
laboratory with the ISO 17025 certification, it could provide
a highly reliable report and reduce potential problems
during the review processes.
Step 5: Send premarket submission to the FDA and
interact with the FDA staff.
After all safety and performance tests are finalized,
applicants must prepare application documents and submit
the 510(k) to the FDA. If successful, they will receive a
510(k) clearance letter from the FDA with a 510(k) number.
The FDA promises to review the submissions within 90 days,
but the timeline can vary depending on the product and the
integrity of the applied documents.
From SCI to FDA 33Materials and methods
Orthopaedic Device Research Center (ODRC, National Yang-
Ming University, Taipei, Taiwan) developed a medical de-
vice which is an antisubsidence dynamic coupling fixation
plate for proximal femur fracture, namely “ODRC dynamic
hip screw system (ODRC-DHS)”. The system consists of
nonsterile ODRC-DHS plates, ODRC-DHS screws, ODRC-DHS
blades, compression screws and 4.5 mm cortex screws
(Figure 1). Results of finite element analysis and biome-
chanical testing showed that this product achieved the
intended purpose effectively. Thus, this product becomes a
candidate for the FDA application.
Step 1
ODRC-DHS system achieves its primary intended purpose
through simple biomechanics. There is no chemical action
and metabolism within or on the body of patients after
implantation. Through querying the FDA classification
database using plate and screw as keywords, the results
showed that this product can be classified as Class II: Plate,
Fixation, Bone (CFR 888.3030) or Class II: Screw, Fixation,
Bone (CFR 888.3040). As the product fully meets the defi-
nition of the FDA Class II medical device, the FDA 510(k)
application process should commence.
Step 2
The FDA 510(k) database was searched and the indications
were compared. The SYNTHES DHS System (K981757) was
chosen as the predicate device of this 510(k) application.
Step 3
In order to meet the biocompatibility considerations, ODRC
outsourced a facility which holds an ISO 13485 certificate toFigure 1 The schematic diagram of the ODRC dynamic hip scre
dynamic hip screw.manufacture the products from the medical grade 316L
stainless steel that meets ASTM F138 [19], ASTM F139 [20]
and ISO 5832-1 [21]. Therefore, the material certification
from the material supplier could be used instead of the
biocompatibility test reports.
According to the characteristics and indications of the
ODRC dynamic hip system, the standards of ASTM F382 [14],
ASTM F384 [22] and ASTM F543 [23] can be found within the
ASTM website. Following the above standards, ODRC
executed biomechanical properties tests of the ODRC dy-
namic hip screw system and the predicate device. The re-
sults indicated that the biomechanical properties of both
products were similar.
Although the ODRC dynamic hip screw system is a non-
sterile product, the sterilization parameters must be pro-
vided in the application documents. Therefore, ODRC
commissioned the Europe America Biotechnology Co., Ltd.
(Taichung, Taiwan) to complete a moist heat validation test
to find the appropriate sterilization parameters. The test
was conducted based upon ISO 17665-1 [24] and ISO 17665-2
[25].
Steps 4 and 5
The application documents should enclose the forms
requested by the FDA, the product descriptions, the engi-
neering drawings, the dimensions and specifications, the
material certification, the biomechanical test report, and
the moist heat sterilization validation test report, etc.
Finally, a comparison table with basic information and
features of both products was created to show that the
ODRC-DHS system and the predicate device were substan-
tially equivalent (Table 3).
Results
The chronicle of the ODRC-DHS system application is listed
as follows:w system. ODRC-DHSZOrthopaedic Device Research Center-
Table 3 Comparison of specific features of new device and legally marketed predicate device.
Comparable features ODRC-DHS system SYNTHES DHS system SE?
510(k) No. (This submission) K981757
Components ODRC-DHS plates
ODRC-DHS screws
ODRC-DHS blades,
compression screw,
and 4.5 mm cortex screw.
DHS plates
Lag screw
compression screw and
Yes
Intended use Fixation of fractures to
the proximal femur
Fixation of fractures
to the proximal femur
Yes
Indication for use The system is indicated for
use in trochanteric,
pertrochanteric, intertrochanteric
and basilar neck fractures.
The system is indicated for use in
trochanteric, pertrochanteric,
intertrochanteric and basilar
neck fractures.
Yes
Material Stainless steel Stainless steel Yes
Use Single use Single use Yes
Method of sterilization Nonsterile Nonsterile Yes
Mechanical testing ASTM F382, F384 and F543 ASTM F382, F384 and F543 Yes
ASTMZ American Society for Testing and Materials; ODRC-DHSZOrthopaedic Device Research Center-dynamic hip screw; SEZ sub-
stantially equivalent.
Figure 2 X-ray images of the implanted ODRC-DHS system.
ODRC-DHSZOrthopaedic Device Research Center-dynamic hip
screw.
34 H.-C. Kao et al.October 8, 2010, submitted to the FDA
October 14, 2010, received an acknowledgement letter
January 11, 2011, received a refuse to accept letter and
an additional information request
April 1, 2011, resubmitted responses to the FDA
April 23, 2011, received a 510(k) decision letter, K103015
Apart from some omissions or unclear instructions that
needed to be amended, the main additional information
requested in this submission was:
“Provide a statement of whether device will be or is
“pyrogen free” and a description of the method used to
make that determination if you are claiming the device
will be pyrogen free.”
Therefore, ODRC commissioned SGS Taiwan Ltd. (Taipei,
Taiwan) to complete a rabbit pyrogen test to determine
whether the device was pyrogen free or not. The test was
conducted based upon the ISO 10993-12 [26] and ISO 10993-
11 [27]. The result concluded that the pyrogen study was
negative, therefore, the test article extract was considered
as “pass” in the pyrogen study.
After reorganizing the application documents by cor-
recting all omissions or unclear instructions and providing
the new study report, ODRC resubmitted the application
documents to the FDA. Fortunately, based on the docu-
ments provided by ODRC, the FDA agreed that ODRC-DHS
system and the predicate device SYNTHES DHS System
(K981757) were substantially equivalent on October 24,
2011. From 2014 to 2015, eleven female osteoporotic pa-
tients with intertrochanteric fractures of the femur and T-
scores under e2.5 were enrolled to a prospective study.
The average age was 82 years old and duration of follow-up
was 90 days to 255 days. The clinical results showed that
there were good fracture unions in the ten patients and no
lag-screw cutout occurred. The postoperative X-ray images
of one patient are shown in Figure 2. The preliminary
follow-up results show that this ODRC-DHS system didreduce lag-screw cutout complications in patients with
osteoporosis [28].
Discussion
Only the FDA 510 (k) process was indicated in this article.
Dynamic hip screw, which has extensive use in orthopae-
dics, is a typical Class II product. If there is a lack of clinical
experience in the use of the product, it may be classified as
Class III, i.e., a higher risk product. In such cases, the
product may need a clinical trial and the FDA PMA process.
In this application, the material certification was used
instead of the biocompatibility test report. In general, ISO
10993 is a part of the international harmonization of the
safety evaluation of medical devices, which entails a series
of standards for evaluating the biocompatibility. ISO 10993-
1:2009 [9] describes the general categorization of devices
based on the nature and duration of their contact with body
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From SCI to FDA 35and suggests the necessity of biocompatibility tests. It will
take a lot of time and cost to complete those tests. Un-
fortunately, the time and funds required for those tests are
far more than general laboratories can afford.
Both raw material and manufacturing process are the
major factors that may induce biocompatibility concerns.
In order to eliminate these concerns, ODRC adopted
commercially available medical grade materials and out-
sourced the products to a facility which holds an ISO 13485
certificate. Therefore, in the case of providing the material
certification alone, the FDA reviewers only requested a
pyrogen study in this application. It took only 2 weeks to
complete this study and cost ODRC approximately $1000,
which would be an affordable cost for laboratories in
universities.
The test methods and executive organizations are the
major factors in the impact of the reliability in a test
report. There were three test reports provided in this
application. Both the moist heat sterilization validation test
report and pyrogen study report were accomplished by ISO
17025 accredited laboratories and followed the relevant
standards. However, the biomechanical test report was
completed by ODRC, which is not an ISO 17025 accreditedlaboratory. The FDA reviewers endorsed this report because
the report was fully in accordance with the relevant stan-
dards. This experience showed that reports from a nonac-
credited laboratory could also provide sufficient reliability
as long as the test was stringently completed.
In addition, a very important thing for the readers to
keep in mind is that the regulations, guidance documents
and standards of medical devices may be modified occa-
sionally. During the development of medical devices, the
manufacturers or regulators should always pay attention to
the updated relevant regulations.
For example, ODRC mailed two hard copies of submis-
sion documents to the FDA for 510(k) application in 2010.
However, the FDA issued a final guidance document enti-
tled “eCopy Program for Medical Device Submissions” on
December 31, 2012 announcing that including an eCopy
with your submission has been required since January 1,
2013. If a submission without or with an eCopy that does not
meet the technical standards outlined in the eCopy guid-
ance, it will be placed on eCopy holds until a valid eCopy is
received. The latest eCopy guidance was issued on
December 3, 2015 [29]. Also, on 25 February, 2016 the ISO
released the ISO 13485:2016. It is the global standard for
Effectiveness
ASTM, ISO standards,
clinical trials
In vitro, in vivo
test
Indications/
contraindications
Safety
Quality
system
ISO 
13485
Figure 4 Essential requirements of FDA /CFDA for medical
implants registration. ASTMZ American Society for Testing
and Materials; CFDAZ China Food and Drug Administration;
FDAZ Food and Drug Administration; GMPZ good
manufacturing practices; ISOZ International Organization for
Standardization.
36 H.-C. Kao et al.medical device quality management systems which will
replace the previous version of 2003. The ISO 13485:2003
and ISO 13485:2016 will coexist for the next three years in
order to allow manufacturers, accreditation/certification
bodies and regulators to have enough time to transit to the
new standards [30].
The traditional flow chart of “From SCI to FDA” is
schematically represented in Figure 3A. The findings or
proving of a concept could be accepted as an SCI paper.
However, more solid and reliable evidence is needed for a
medical device. As well as indications/contraindications
and effectiveness which are indispensable to a medical
device, public authorities pay more attention to the risks
and quality control of devices (Figure 4). Our regular
practice is a scientific development followed by a trans-
lational research, which is time-consuming and costly.
However, publishing SCI papers is not usually contrary to
the FDA application. The laboratory test results could be
used as the FDA 510 (k) application documents as long as
the testing specimen processes and reports meet the latest
regulatory considerations. Therefore, the authors would
like to recommend that researchers should include regu-
lation considerations during the development period, which
could reduce the time and cost of the translational
research. The modified flow chart of “From SCI to FDA” is
shown in Figure 3B.
Translational research is not difficult providing it meets
the regulatory requirements. However, less than 20% of
medical device value is engineering related and more than
50% is created by market channel [31]. Therefore, a suc-
cessful translational research must prove that new medical
devices can provide better results than current treatments
in order to facilitate the promotion and marketing ofproducts. In addition, intellectual property will provide
adequate protection against counterfeiting of products. It
is very important for researchers to apply for a patent
before SCI publication and license application.
Conclusion
A SCI paper, which describes whether a certain idea or
concept is correct or not, is a scientific achievement.
However, translational research should be encouraged in
order to translate the research results into medical devices
and promote public welfare. The development of medical
devices seems complicated, but is simple in nature.
Although a lot of scientific evidence must be prepared, the
translational work can be completed smoothly by reading
and following all the existing guidance documents, di-
rectives, and standards carefully.
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